Stoke Therapeutics (STOK) Amortizatization of Intangibles (2021 - 2026)
Stoke Therapeutics' quarterly Amortizatization of Intangibles came in at -$365000.0 in Q1 2026, up 26.11% year-on-year from -$289422.2 in Q1 2025, and up 33.76% quarter-over-quarter from -$551000.0 in Q4 2025.
Stoke Therapeutics has reported Amortizatization of Intangibles for 6 years, with the latest figure at -$365000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles rose 26.11% year-over-year to -$365000.0; the trailing twelve-month figure through Mar 2026 stood at -$1.0 million (up 52.46% YoY), and the FY2025 full-year result was -$1.1 million, up 31.0% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at -$365000.0, up from -$551000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $527000.0 in Q2 2025, with the low at -$782000.0 in Q4 2024.
- Average Amortizatization of Intangibles over 5 years is -$216235.3, with a median of -$151000.0 recorded in 2022.
- Peak annual rise in Amortizatization of Intangibles reached 282.35% in 2025, while the deepest fall reached 1958.33% in 2025.
- Tracing STOK's Amortizatization of Intangibles over 5 years: stood at -$151000.0 in 2022, then soared by 41.06% to -$89000.0 in 2023, then plunged by 778.65% to -$782000.0 in 2024, then climbed by 29.54% to -$551000.0 in 2025, then surged by 33.76% to -$365000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at -$365000.0 (Q1 2026), -$551000.0 (Q4 2025), and -$615000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - | -365,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -365,000.00 |
| Mar 31, 2026 | -365,000.00 |
| Dec 31, 2025 | -551,000.00 |
| Dec 31, 2025 | -551,000.00 |
| Sep 30, 2025 | -615,000.00 |
| Sep 30, 2025 | -615,000.00 |
| Jun 30, 2025 | 527,000.00 |
| Jun 30, 2025 | 527,000.00 |
| Mar 31, 2025 | -494,000.00 |
| Mar 31, 2025 | -494,000.00 |
| Dec 31, 2024 | -782,000.00 |
| Dec 31, 2024 | -782,000.00 |
| Sep 30, 2024 | -547,000.00 |
| Sep 30, 2024 | -547,000.00 |
| Jun 30, 2024 | -289,000.00 |
| Jun 30, 2024 | -289,000.00 |
| Mar 31, 2024 | -24,000.00 |
| Mar 31, 2024 | -24,000.00 |
| Dec 31, 2023 | -89,000.00 |
| Dec 31, 2023 | -89,000.00 |
| Sep 30, 2023 | -122,000.00 |
| Sep 30, 2023 | -122,000.00 |
| Jun 30, 2023 | -146,000.00 |
| Jun 30, 2023 | -146,000.00 |
| Mar 31, 2023 | 32,000.00 |
| Mar 31, 2023 | 32,000.00 |
| Dec 31, 2022 | -151,000.00 |
| Dec 31, 2022 | -151,000.00 |
| Sep 30, 2022 | -102,000.00 |
| Sep 30, 2022 | -102,000.00 |
| Jun 30, 2022 | -193,000.00 |
| Jun 30, 2022 | -193,000.00 |
| Mar 31, 2022 | 235,000.00 |
| Mar 31, 2022 | 235,000.00 |
| Dec 31, 2021 | 57,000.00 |
| Dec 31, 2021 | 57,000.00 |
| Sep 30, 2021 | 49,000.00 |
| Sep 30, 2021 | 49,000.00 |